FDA Advisers Recommend Full Approval of Pfizer's Paxlovid as COVID-19 Treatment.
TL;DR Summary
Pfizer's COVID-19 pill, Paxlovid, has received a positive vote from a panel of U.S. health advisers, paving the way for full regulatory approval by the FDA. The medication has been used by millions of Americans since receiving emergency use authorization in late 2021. The FDA is expected to make a final decision by May. Paxlovid has been found to be a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus. The FDA estimates that using Paxlovid in high-risk patients could prevent 1,500 COVID-19 deaths and 13,000 hospitalizations per week.
- COVID-19 Pill Paxlovid Moves Closer To Full FDA Approval HuffPost
- F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment The New York Times
- FDA AdComm recommends Pfizer's Paxlovid for full approval FiercePharma
- FDA Advisers Support Full Approval of Paxlovid Newser
- FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people CNBC
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
83%
600 → 102 words
Want the full story? Read the original article
Read on HuffPost